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Abstract: Background 
Prostate cancer is the second most common cancer in the UK, with 39,741 
cases diagnosed in 2014. The NCRAS collects cancer data from across 
England, including prostate cancer cases. The CAP study is a cluster 
randomised controlled trial investigating the effectiveness and cost-
effectiveness of prostate-specific antigen (PSA) testing. The value of 
cancer registries is maximised by receiving and processing quality data, 
and they can be evaluated in a number of domains, including completeness 
and validity. This studied aimed to compare the completeness and accuracy 
of the NCRAS registry and CAP study diagnosis and staging/grade data. 
 
Methods 
We compared the percentage completeness and agreement of prostate cancer 
diagnosis Union Internationale Contre le Cancer (UICC) Tumour-Node-
Metastasis (TNM) stage and Gleason grade data in the NCRAS cancer 
registry with information collected via independent medical record review 
on 1,356 participants in CAP, a large prostate cancer screening trial. 
CAP study participants were matched to NCRAS registry entries using their 
NHS number. Agreement was assessed using Cohen's Kappa.  
 
Findings 
The mean age of the 1,356 men included in this study was 75.15 years (SD 
5.09). Both the NCRAS (97.86%) registry and CAP study (98.53%) had high 
levels of completeness for diagnosis date. Kappa agreement was 0.90 (95% 
CI 0.89, 0.92) for combined Gleason score, and 0.48 (0.43, 0.53) for 
American Joint Committee on Cancer (AJCC) group. TNM staging agreement 
was 0.35 (0.31, 0.37) for T, 0.51 (0.45, 0.57) for N, and 0.58 (0.51, 
0.66) for M stage overall. Agreement was moderate when considering local 
(T1-3N0M0) vs metastatic disease (T4NxMx / TxN1Mx / TxNxM1) (k=0.54 95% 
CI 0.44, 0.64). 
 
Interpretation 
The NCRAS prostate cancer registry appears to have a high level of 
completeness for case registration, and strong accuracy for Gleason 
grade. Agreement of exact TNM staging and AJCC group appears to be low, 
which could be explained if staging data was collected from different 
sources (i.e. pathological vs. imaging staging methods) and needs to be 
explored further. Prostate cancer stage and grade data accuracy for the 
NCRAS registry need repeated evaluation to drive improvements in data 
quality. 
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registries is maximised by receiving and processing quality data, and they can be evaluated 
in a number of domains, including completeness and validity. This studied aimed to compare 
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Interpretation 
The NCRAS prostate cancer registry appears to have a high level of completeness for case 
registration, and strong accuracy for Gleason grade. Agreement of exact TNM staging and 
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AJCC group appears to be low, which could be explained if staging data was collected from 
different sources (i.e. pathological vs. imaging staging methods) and needs to be explored 
further. Prostate cancer stage and grade data accuracy for the NCRAS registry need repeated 
evaluation to drive improvements in data quality. 
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Background 
Prostate cancer is the second most common cancer in the UK, with 39,741 cases diagnosed 
in 2014. The National Cancer Registry Service (NCRS)NCRAS collects cancer data from across 
England, including prostate cancer cases. The Cluster randomised TriAl of PSA testing for 
Prostate cancer (CAP) study is a cluster randomised controlled trial investigating the 
effectiveness and cost-effectiveness of prostate-specific antigen (PSA) testing. The value of 
cancer registries is maximised by receiving and processing quality data, and they can be 
evaluated in a number of domains, including completeness and validity. This studied aimed 
to compare the completeness and accuracy of the NCRAS registry and CAP study diagnosis 
and staging/grade data. 
 
Methods 
We compared the percentage completeness and agreement of prostate cancer diagnosis 
Union Internationale Contre le Cancer (UICC) Tumour-Node-Metastasis (TNM) stage and 
Gleason grade data in the NCRAS cancer registry with information collected via independent 
medical record review on 1,356 participants in CAP, a large prostate cancer screening trial. 
CAP study participants were matched to NCRAS registry entries using their NHS number. 
Agreement was assessed using Cohen’s Kappa.  
Patients’ data in NCRS prostate cancer registry and/or the CAP trial between Feb 2002 and 
Dec 2015 were merged using a unique identifier. Chi-square tests and Kappa statistic 
calculations were performed to confirm the accuracy and completeness of NCRS prostate 
cancer registry data, relative to the CAP trial data. 
 
Findings 
Data were obtained from NCRS or CAP (or both) forThe mean age of the 1,356 men included 
in this study was 75.15 years (SD 5.09). Both tThe NCRAS (97.86%) registry and CAP study 
(98.53%) had high levels of completeness for diagnosis date., with 26 (1.92%) of men from 
NCRS missing a date of diagnosis. Kappa agreement on staging was 0.90 (95% CI 0.89, 0.92) 
for combined Gleason score, and 0.48 (0.43, 0.53) for American Joint Committee on Cancer 
(AJCC) group. TNM staging agreement was 0.35 (0.31, 0.37) for T, 0.51 (0.45, 0.57) for N, and 
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0.58 (0.51, 0.66) for M stage overall. Agreement was moderate when considering local (T1-
3N0M0) vs metastatic disease (T4NxMx / TxN1Mx / TxNxM1) (k=0.54 95% CI 0.44, 0.64). 
 
Interpretation 
The NCRAS prostate cancer registry appears to have a high level of completeness for case 
registration, and strong accuracy for Gleason grade. Agreement of exact TNM staging and 
AJCC group appears to be low, which could be explained if staging data was collected from 
different sources (i.e. pathological vs. imaging staging methods) and needs to be explored 
further. Accurate cancer registry data is needed to inform allocation of the limited funds 
available for cancer treatment and prevention.Prostate cancer stage and grade data 
accuracy for the NCRAS registry need repeated evaluation to drive improvements in data 
quality. 
 
Word count – 343297 (excluding authors) 
 
 
Funding 
This research project did not receive any funding. The CAP trial is funded by Cancer Research 
UK and the UK Department of Health (C11043/A4286, C18281/A8145, C18281/A11326 and 
C18281/A15064). 
 
Contributions 
ET co-ordinated CAP trial data collection, overseen by RM, FH, DN and JD. EW extracted CAP 
trial data for this study. LH and IT extracted NCRAS data. SM performed analysis with 
assistance from GY and CM.  SM drafted abstract, with input from all authors. 
 
Conflicts of interest 
We declare we have no conflicts of interest 
 
Acknowledgements 
The authors would like to acknowledge Cancer Research UK, and the Public Health England 
Knowledge Intelligence TeamNational Cancer Registration and Analysis Service South-West, 
and the CAP trial group. 
Responses to reviewer comments 
 
Editorial comments: 
Please ensure that your revised abstract is shorter than 350 words (excluding author details 
and funding, contributors, and competing interest statements). 
The abstract word count is 343 
Please indicate in your revised Word document whether you are an early career researcher. 
The covering letter has been amended to confirm the corresponding author is an early 
career researcher 
Please finalise authorship of your abstract before submitting your revised version. 
Authorship has been finalised, and all authors have signed the author statement form 
Please state study aim in background 
The aim of the study has been added to the background section 
 
Reviewer #1 
This abstract is interesting in as far as it goes in that the validity of cancer registries is an 
important area for public health. 
Thank you for your comment 
The approach here seem sensible, looking agreement between the bespoke trial data and 
registry data using kappa test, with appropriate presentation of statistical uncertainty 
around these estimates. 
Thank you for your comment 
Reassuring levels of completeness are reported for the registry data. The issue highlighted 
here is around the relative lack of agreement between the two dated sources around 
staging. I find it hard to believe that this is anything other than a reflection of the fact that 
the two data sources are likely to be looking at two different things. I think it highly probable 
that the two data sources report at different times, using slightly different methods and 
what this difference is telling us is not so much about the validity of the cancer registry but 
about the complexity and consequent variation around staging cancers. 
Thank you for your comment. Unfortunately this study was not designed to determine why 
differences between the data sources may exist. This would indeed be an interesting further 
exploration. 
Nevertheless I recommend that the abstract be accepted in its current state as this is 
highlighting an important potential problem that needs further more detailed investigation. 
Thank you for your comment 
 
Reviewer #2 
This appears to be a development / proof of principle piece of work validating national 
cancer registry data against data from a prostate cancer cluster randomised trial. Overall, 
the abstract is well written and clear, with the interpretation clearly supported by the 
findings. 
Thank you for your comment 
What this abstract lacks is a clear statement of objective / hypothesis. It would also benefit 
the abstract to clearly explain why it is helpful to validate cancer registry data in this way. 
The aim of the study has been added to the background section 
 
Reviewer #3: 
Prostate cancer is the second most common cancer in England and has the fifth highest 
burden of all cancers when measured in DALYs. England also has a world leading cancer 
registry. This study looked a validating registry data against those collected from a 
Reviewer comment responses
randomized controlled trial. The authors should attempt to address the following: 
The aim of this study should be explicitly stated as it's currently unclear. 
The aim of the study has been added to the background section 
What unique identifier was used to match across the trial and NCRS datasets, and were all 
records matched? 
Participants were matched using their NHS numbers. Not all participants in the CAP study 
had complete NCRAS registry data. 
Were all CAP participants found in the registry as it seems like this was the way the dataset 
were combined despite wording in abstract (see later point)? 
See comment above 
Completeness of data in the registry was mentioned, but not the trial dataset. 
Completeness for CAP study data has been added to the Findings section 
TNM should be defined at first use. 
TNM has now been defined in its first in the Methods section 
The statement 'or both' in the findings: "Data were obtained from NCRS or CAP (or both)" is 
confusing. Is it not the case that NCRS data were compared to CAP by only including those 
individuals in NCRS that also took part in the CAP trial? If not, please clarify how missing 
data/ participants were dealt with. 
Apologies for the confusing wording. Further information about participant selection has 
been added to the Methods section. 
Were there any other missing data in NCRS other than date of diagnosis? 
Yes. There was missing data for stage and grade in both the NCRAS registry and CAP study. 
Unfortunately, we are unable to present all of our findings in the abstract owing to the word 
limit. 
The concluding sentence "Accurate cancer registry data is needed to inform allocation of the 
limited funds available for cancer treatment and prevention." is rather general. It would be 
more helpful to propose a way forward for improving NCRS based on the findings of the 
study. 
Thank you. The Interpretation section has been amended to better reflect on the study 
findings. 
